DOCSLIB.ORG

The Controlled Drugs and Substances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Controlled Drugs and Substances S C H E D U L E I S C H E D U L E I I I S C H E D U L E I V I N D E X The Controlled Drugs 9. Moramides, their intermediates, salts, derivatives and salts of intermediates and derivatives including: 1. Amphetamines, their salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues including: 18. Benzodiazepines, their salts and derivatives, including: Substances are listed alphabetically, ignoring spaces, digits, Greek letters, and single-letter qualifiers such as p-, N-, N,N-, (1) Dextromoramide (2) Diphenylmorpholino~ (3) Levomoramide (4) Racemoramide (1) Amphetamine (3) N-Ethyl~ (4) 4-Methyl- (5) 3,4-Methylenedioxy~ (6) 2,5-Dimethoxy~ (1) Alprazolam (2) Bromazepam(2.1) Brotizolam (3) Camazepam (4) Chlordiazepoxide (5) Clobazam amphetamine 2,5-dimethoxy~ amphetamine (MDA) amphetamine α-, and β-. For example: isovaleric acid N O N O N O amphetamine (STP) N N H HN N N N O O O O O NH N,N-Dimethyltryptamine is indexed under D and Substances Act NH2 N O NH2 NH2 2 N N O α S N -Methylfentanyl is indexed under M N N N N 2,4,5-Trimethoxyamphetamine is indexed under T N N N N O O N Br N O O O O Br Cl Cl Cl Schedules & Structures O Cl N Cl (7) 4-Methoxy~ (8) 2,4,5-Trimethoxy~ (9) N-Methyl- (10) 4-Ethoxy- (11) 5-Methoxy- Acetic anhydride VI.1.1 Lormetazepam IV.18.(21) amphetamine amphetamine 3,4-methylenedioxy~ 2,5-dimethoxy~ 3,4-methylenedioxy~ Acetone VI.2.1 LSD III.5 STEVE CHAPMAN amphetamine amphetamine amphetamine Acetorphine I.1.(5) Lysergic acid VI.1.8 H (6) Clonazepam (7) Clorazepate (8) Cloxazolam (9) Delorazepam (10) Diazepam (11) Estazolam N-Acetylanthranilic Lysergic acid NH2 O NH2 N O NH2 O NH2 ON OOH ON ON O O O O N acid VI.1.2 diethylamide III.5 HO OH N Acetyldihydro~ HN OH HN HN N HN codeine I.1.(6) Marihuana II.1.(2) O O O O O O O N S C H E D U L E I Acetylmethadol I.6.(1) Mazindol IV.15 10. Morphinans, their salts, derivatives and salts of derivatives including: O O N O N N N α N Acetyl- -methyl~ MDA III.1.(5) O N fentanyl I.16.(1) Mebolazine IV.23.(19) 1. Opium poppy (Papaver somniferum), its preparations, derivatives, alkaloids and salts, including: (1) Buprenorphine (2) Drotebanol (3) Levomethorphan (4) Levorphanol (5) Levophenacylmorphan N Cl Cl Cl (12) N,N-Dimethyl- (13) N-Ethyl- (14) 4-Ethyl- (15) 4-Bromo- (16) 4-Chloro- Cl Cl O Cl Cl Alfentanil I.16.(2) Mecloqualone III.4 3,4-methylenedioxy~ 3,4-methylenedioxy~ 2,5-dimethoxy~ 2,5-dimethoxy~ 2,5-dimethoxy~ O (1) Opium (2) Codeine (3) Morphine (4) Thebaine O Allobarbital IV.1.(1) Medazepam IV.18.(22) N N N amphetamine amphetamine amphetamine (DOET) amphetamine amphetamine Cl N N N Allylprodine I.3.(1) Mefenorex IV.22 [Opium, the dried sap of the H Alphacetylmethadol I.6.(2) Mephobarbital IV.1.(16) N N O NH HO H H N N 2 O NH2 O NH2 Opium poppy seed head, is a H H Alphameprodine I.3.(2) Meprobamate IV.16 complex mixture of chemicals (12) Ethyl loflazepate (13) Fludiazepam (15) Flurazepam (16) Halazepam (17) Haloxazolam (18) Ketazolam Alphamethadol I.6.(3) Mesabolone IV.23.(20) H F O O including Codeine, Morphine, O O O Br O Cl O N Alphaprodine I.3.(3) Mescaline III.17 Thebaine and Papaverine.] OH F O O OH O HO O O O O O O HN N Alphenal IV.1.(2) Mesocarb III.30 O O OH HO O OH O O O O F Alprazolam IV.18.(1) Mesterolone IV.23.(21) HN N N N HO O O HO Amidones etc. I.5 Metandienone IV.23.(22) (17) 4-Ethoxy~ (18) Benzphetamine (19) N-Propyl- (20) N-(2-Hydroxyethyl)- (21) N-Hydroxy- N N O [A]nd the salts, derivatives and salts of derivatives of the substances set out in subitems (1) to (4), including: α O Amineptine III.32 Metazocine I.11.(2) amphetamine 3,4-methylenedioxy~ -methyl~ 3,4-methylenedioxy~ N N N N Br Cl Aminorex III.27 Metenolone IV.23.(23) (5) Acetorphine (6) Acetyldihydrocodeine (7) Benzylmorphine N (8) Codoxime (6) Norlevorphanol (7) Phenomorphan (8) Racemethorphan (9) Racemorphan amphetamine benzeneethanamine amphetamine O O Cl Cl Cl Cl Amobarbital IV.1.(3) Metethoheptazine I.4.(3) H F F F N N N H H F Amphetamine III.1.(1) Methabarbital IV.1.(17) H NH2 N N N N NH N N N OH OH Amphetamines etc. III.1 Methadols etc. I.6 Ampromides etc. I.12 Methadone I.5.(4) H H N Anabolic steroids etc. IV.23 Methamphetamine I.18 O O O N OH H H H H (19) Loprazolam (20) Lorazepam (21) Lormetazepam (22) Medazepam(22.1) Midazolam (23) Nimetazepam Androisoxazole IV.23.(1) Methamphetamine III.1.(23) O O OH O O O O but not including: O O N O Androstanolone IV.23.(2) Methandriol IV.23.(24) O O O O O O O O N O O O Androstenediol IV.23.(3) Methaqualone III.3 (22) 3,4,5-Trimethoxy~ (23) Methamphetamine N HN N N N HO HO O HO OH OH Anileridine I.3.(4) Metheptazine I.4.(4) amphetamine N N OH H Anthranilic acid VI.1.3 4-Methoxy~ N N N N N but not including: O NH2 Apomorphine I.1.(32) amphetamine III.1.(7) (9) Desomorphine (10) Diacetylmorphine (Heroin) (11) Dihydrocodeine (12) Dihydromorphine (13) Ethylmorphine N O N Cl Cl Cl N Aprobarbital IV.1.(4) 5-Methoxy- Cl Cl N O Cl N N N N (10) Dextromethorphan (11) Dextrorphan (12) Levallorphan (13) Levargorphan (14) Butorphanol (15) Nalbuphine O N F O 3,4-methylenedioxy~ Cl Barbital IV.1.(5) amphetamine III.1.(11) O O H H H H H N N N N N N Barbiturates etc. IV.1 2-Methylamino-1-phenyl- Barbituric acid IV.1.(6) 1-propanone III.21 Benzazocines etc. I.11 4-Methylaminorex III.18 O O H H H H HO HO 2. Methylphenidate 3. Methaqualone 4. Mecloqualone 5. Lysergic acid 6. N,N-Diethyl~ (24) Nitrazepam (25) Nordazepam (26) Oxazepam (27) Oxazolam (28) Pinazepam (29) Prazepam Benzethidine I.3.(7) Methyldesorphine I.1.(18) HO O O O O O O OH O O and any salt thereof and any salt thereof and any salt thereof diethylamide (LSD) tryptamine (DET) HO OH O OH O O O O O Benzimidazoles etc. I.13 Methyldihydro~ and any salt thereof and any salt thereof O Benzodiazepines etc. IV.18 morphine I.1.(19) N HN HN HN HN N O HO HO HO HO HO O OH O O N OH N Benzphetamine III.1.(18) 4-Methyl-2,5-dimethoxy~ (14) Etorphine (15) Hydrocodone (16) Hydromorphinol (17) Hydromorphone (18) Methyldesorphine H Benzylmorphine I.1.(7) amphetamine III.1.(4) N N N O N N N N N N N N N N N 11. Benzazocines, their salts, derivatives and salts of derivatives including: but not including: Betacetylmethadol I.6.(4) 3,4-Methylenedioxy~ O N N N Cl Cl Cl Cl O Betameprodine I.3.(5) amphetamine III.1.(5) (1) Phenazocine (2) Metazocine (3) Pentazocine (4) Cyclazocine O O H Cl H HO H H Cl N O Betamethadol I.6.(5) 3,4-Methylenedioxy~ N H OH Betaprodine I.3.(6) phenyl-2-propanone VI.1.9 N N N N H Bezitramide I.13.(3) Methyl ethyl ketone VI.2.4 7. N,N-Dimethyl~ 8. N-Methyl-3-piperidyl 9. Harmaline 10. Harmalol Bolandiol IV.23.(4) 3-Methylfentanyl I.16.(10) O O O O O HO O OH HO HO O O HO O tryptamine (DMT) benzilate (LBJ) and any salt thereof and any salt thereof (29.1) Quazepam (30) Temazepam (31) Tetrazepam (32) Triazolam Bolasterone IV.23.(5) α-Methylfentanyl I.16.(8) and any salt thereof and any salt thereof F O O N Bolazine IV.23.(6) N-Methyl- (19) Methyldihydromorphine (20) Metopon (21) Morphine-N-oxide (22) Myrophine (23) Nalorphine N Boldenone IV.23.(7) 3,4-methylenedioxy~ N F S N N O H Bolenol IV.23.(8) amphetamine III.1.(9) N N OH N N HO HO HO HO N F N Bromazepam IV.18.(2) Methylphenidate III.2 N N N N O N HO N O H H N N 4-Bromo-2,5-dimethoxy~ Methylphenobarbital IV.1.(18) N H HO N amphetamine III.1.(15) 1-[1-(4-Methylphenyl)~ N Cl Cl H H H H 12. Ampromides, their salts, derivatives 13. Benzimidazoles, their salts, derivatives O Cl 4-Bromo-2,5-dimethoxy~ cyclohexyl]piperidine III.23 H Cl Cl O and salts of derivatives including: and salts of derivatives including: N F benzeneethanamine III.24 Methylphenyl~ Brotizolam IV.18.(2.1) isonipecotonitrile I.3.(14) OH O O O (1) Diampromide (2) Phenampromide (3) Propiram (1) ClonitazeneCl (2) Etonitazene O HO O HO O O HO O OH HO O OH Buprenorphine I.10.(1) N-Methyl-3-piperidyl 11. Psilocin 12. Psilocybin 13. N-(1-Phenylcyclohexyl)~ 14. 1-[1-(2-Thienyl)cyclo~ Butabarbital IV.1.(7) benzilate III.8 O O and any salt thereof and any salt thereof ethylamine (PCE) hexyl]piperidine (TCP) but not including: Butalbital IV.1.(8) Methyltestosterone IV.23.(25) N N N N Butallylonal IV.1.(9) 3-Methylthiofentanyl I.16.(11) O O OH and any salt thereof and any salt thereof (32.1) Clozapine (33) Flunitrazepam (34) Olanzapine (24) Nicocodine N (25) NicomorphineN (26) Norcodeine (27) Normorphine O 1,4-Butanediol VI.1.19 α-Methylthiofentanyl I.16.(9) N N N P Butethal IV.1.(10) Methyprylon IV.17 NH NH N N OH O Cl O H H HO HN HN Butorphanol I.10.(14) Metopon I.1.(20) N NH N N N S S Butorphanol IV.9 Metribolone IV.23.(26) H H N N N N N N N Mibolerone IV.23.(27) O O O N N Calusterone IV.23.(9) Midazolam IV.18.(22.1) O O O O O O N O H H N N N Camazepam IV.18.(3) Moramides etc.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Emergency Department Requirement for Assessment of Outpatients Who Receive Injectable Narcotics
    This is an Interior Health CONTROLLED document. A copy of this document in paper form is not controlled and should be checked against the electronic file version to ensure accuracy Administrative Policy Manual Code: AH Patient/Client Relations/Care AH0600 - EMERGENCY DEPARTMENT REQUIREMENT FOR ASSESSMENT OF OUTPATIENTS WHO RECEIVE INJECTABLE NARCOTICS 1.0 PURPOSE To promote quality care and patient safety by ensuring Outpatients are appropriately assessed by an EDP or MRP when receiving or prior to receiving an injectable Narcotic in Emergency Departments (ED) of Interior Health (IH). 2.0 DEFINITIONS EDP Emergency Department Physician MRP Most Responsible Physician Narcotic Any substance set out in the schedule or anything that contains any substance set out in the schedule in the (Narcotic Control Regulations, CRC. C., 1041), see Appendix B. Outpatient A patient who presents to the ED for care and is not hospitalized or admitted to hospital. 3.0 POLICY 3.1 Assessment and Order Required This policy applies to Narcotic injection(s) administered to Outpatients being treated for acute and/or chronic conditions at IH EDs. Narcotic injection(s) will only be administered to Outpatients when the Outpatient has been assessed by an EDP/MRP (with active privileges in the administering facility) and the EDP/MRP has written an order dated within 24 hours of the Narcotic injection being administered. NOTE: Phone orders are acceptable on the undertaking the EDP/MRP will assess the Outpatient within 24 hours of the phone order. Orders for a series of Narcotic injections in excess of 24 hours require Outpatients be reassessed by an EDP/MRP (with active privileges in the administering facility) within 24 hours of the initial order and within every 24 hours thereafter while the Narcotic injection order is in effect.
    [Show full text]
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • Laws and Regulations Promulgated to Give Effect to the Provisions of the International Treaties on Narcotic Drugs and Psychotropic Substances
    UNITED NATIONS E/NL. 1978/57-59 15 October 1981 ENGLISH ONLY LAWS AND REGULATIONS PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE INTERNATIONAL TREATIES ON NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES SPAIN Communicated by the Government of Spain NOTE BY THE SECRETARY-GENERAL - In accordance with the relevant Articles of the International Treaties on Narcotic Drugs and Psychotropic Substances, the Secretary-General has the honour to communicate the following legislative texts. INDEX E/NL.1978/57 Order of 11 May 1977 concerning medical prescriptions .. E/NL.1978/58 Decision of the Department of Health concerning the classification of proprietary medicines in accordance with the therapeutic index E/NL.1978/59 Royal Decree No. 2829 of 6 October 1977 regulating psychotropic medicinal substances and preparations and the control and inspection of the manufacture, distribution, prescription and dispensing of such substances and preparations E/NL.1978/57 Official Gazette No. 129 31 May 1977 MINISTRY OF THE INTERIOR 12918 ORDER of 11 May 1977 concerning medical prescriptions Sir, In viev of the appearance of new medicaments and of more modern therapeutic methods, it has become advisable to bring up to date the Order of this Ministry dated Ik August 1965 concerning the dispensing of medical preparations and proprietary medicines, with a view to ensuring maximum efficacy and health control in the use of medical preparations and proprietary medicines. Accordingly, this Ministry has decided to mate the following Order: 1. "Medical prescription" means the document whereby a medical practitioner prescribes the medication to be administered to the patient and to be dispensed by a pharmacy.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • Controlled Drugs and Substances Act Loi Réglementant Certaines
    CANADA CONSOLIDATION CODIFICATION Controlled Drugs and Loi réglementant Substances Act certaines drogues et autres substances S.C. 1996, c. 19 L.C. 1996, ch. 19 Current to October 27, 2015 À jour au 27 octobre 2015 Last amended on July 16, 2015 Dernière modification le 16 juillet 2015 Published by the Minister of Justice at the following address: Publié par le ministre de la Justice à l’adresse suivante : http://laws-lois.justice.gc.ca http://lois-laws.justice.gc.ca OFFICIAL STATUS CARACTÈRE OFFICIEL OF CONSOLIDATIONS DES CODIFICATIONS Subsections 31(1) and (2) of the Legislation Les paragraphes 31(1) et (2) de la Loi sur la Revision and Consolidation Act, in force on révision et la codification des textes législatifs, June 1, 2009, provide as follows: en vigueur le 1er juin 2009, prévoient ce qui suit : Published 31. (1) Every copy of a consolidated statute or 31. (1) Tout exemplaire d'une loi codifiée ou d'un Codifications consolidation is consolidated regulation published by the Minister règlement codifié, publié par le ministre en vertu de comme élément evidence under this Act in either print or electronic form is ev- la présente loi sur support papier ou sur support élec- de preuve idence of that statute or regulation and of its contents tronique, fait foi de cette loi ou de ce règlement et de and every copy purporting to be published by the son contenu. Tout exemplaire donné comme publié Minister is deemed to be so published, unless the par le ministre est réputé avoir été ainsi publié, sauf contrary is shown.
    [Show full text]